<DOC>
	<DOC>NCT02755337</DOC>
	<brief_summary>To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.</brief_summary>
	<brief_title>The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase</brief_title>
	<detailed_description>Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a positive EGFR mutation. Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib. Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>NSCLC based on histopathologic examination Adenocarcinoma and/or nonadenocarcinoma based on histology examination Clinical stadium stage IIIB and IV Age 1670 years old Received gefitinib as therapy At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period from January 2013 until July 2015 Missing data of any variables of the treatment outcomes in the medical record</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>non-adenocarcinoma</keyword>
</DOC>